The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein: based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995
Gespeichert in:
| Format: | Tagungsbericht Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Oxford [u.a.]
Pergamon
1997
|
| Schriftenreihe: | [European journal of cancer / Supplement]
33,1 |
| Schlagworte: | |
| Beschreibung: | 36 S. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV011320311 | ||
| 003 | DE-604 | ||
| 005 | 19970522 | ||
| 007 | t| | ||
| 008 | 970425s1997 xx |||| 10||| eng d | ||
| 035 | |a (OCoLC)1072736974 | ||
| 035 | |a (DE-599)BVBBV011320311 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 |a DE-19 |a DE-20 | ||
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein |b based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 |c P. E. Postmus, guest ed. |
| 264 | 1 | |a Oxford [u.a.] |b Pergamon |c 1997 | |
| 300 | |a 36 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a [European journal of cancer / Supplement] |v 33,1 | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1995 |z Paris |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Postmus, Pieter E. |e Sonstige |4 oth | |
| 711 | 2 | |a European Conference on Clinical Oncology and Cancer Nursing |n 8 |d 1995 |c Paris |j Sonstige |0 (DE-588)5160324-X |4 oth | |
| 810 | 2 | |a Supplement] |t [European journal of cancer |v 33,1 |w (DE-604)BV001893745 |9 33,1 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-007605519 | |
Datensatz im Suchindex
| _version_ | 1823607494769901568 |
|---|---|
| adam_text | |
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV011320311 |
| classification_rvk | XH 3200 |
| ctrlnum | (OCoLC)1072736974 (DE-599)BVBBV011320311 |
| discipline | Medizin |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV011320311</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19970522</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">970425s1997 xx |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1072736974</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011320311</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein</subfield><subfield code="b">based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995</subfield><subfield code="c">P. E. Postmus, guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford [u.a.]</subfield><subfield code="b">Pergamon</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">36 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">[European journal of cancer / Supplement]</subfield><subfield code="v">33,1</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1995</subfield><subfield code="z">Paris</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Postmus, Pieter E.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="711" ind1="2" ind2=" "><subfield code="a">European Conference on Clinical Oncology and Cancer Nursing</subfield><subfield code="n">8</subfield><subfield code="d">1995</subfield><subfield code="c">Paris</subfield><subfield code="j">Sonstige</subfield><subfield code="0">(DE-588)5160324-X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="810" ind1="2" ind2=" "><subfield code="a">Supplement]</subfield><subfield code="t">[European journal of cancer</subfield><subfield code="v">33,1</subfield><subfield code="w">(DE-604)BV001893745</subfield><subfield code="9">33,1</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007605519</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1995 Paris gnd-content |
| genre_facet | Konferenzschrift 1995 Paris |
| id | DE-604.BV011320311 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-09T19:00:30Z |
| institution | BVB |
| institution_GND | (DE-588)5160324-X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007605519 |
| oclc_num | 1072736974 |
| open_access_boolean | |
| owner | DE-29 DE-19 DE-BY-UBM DE-20 |
| owner_facet | DE-29 DE-19 DE-BY-UBM DE-20 |
| physical | 36 S. |
| publishDate | 1997 |
| publishDateSearch | 1997 |
| publishDateSort | 1997 |
| publisher | Pergamon |
| record_format | marc |
| series2 | [European journal of cancer / Supplement] |
| spelling | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 P. E. Postmus, guest ed. Oxford [u.a.] Pergamon 1997 36 S. txt rdacontent n rdamedia nc rdacarrier [European journal of cancer / Supplement] 33,1 Cytostatikum (DE-588)4068347-3 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1995 Paris gnd-content Krebs Medizin (DE-588)4073781-0 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Cytostatikum (DE-588)4068347-3 s Postmus, Pieter E. Sonstige oth European Conference on Clinical Oncology and Cancer Nursing 8 1995 Paris Sonstige (DE-588)5160324-X oth Supplement] [European journal of cancer 33,1 (DE-604)BV001893745 33,1 |
| spellingShingle | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 Cytostatikum (DE-588)4068347-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4076066-2 (DE-588)4073781-0 (DE-588)1071861417 |
| title | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 |
| title_auth | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 |
| title_exact_search | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 |
| title_full | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 P. E. Postmus, guest ed. |
| title_fullStr | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 P. E. Postmus, guest ed. |
| title_full_unstemmed | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 P. E. Postmus, guest ed. |
| title_short | The management of cancer patients: separate research experiences with gemcitabine HCl and DAB 389 IL-2 fusion protein |
| title_sort | the management of cancer patients separate research experiences with gemcitabine hcl and dab 389 il 2 fusion protein based on scientific proceedings of an eli lilly and company satellite symposium at the 8th european conference on clinical oncology and cancer nursing in paris 29 october 2 november 1995 |
| title_sub | based on scientific proceedings of an Eli Lilly and Company satellite symposium at the 8th European Conference on Clinical Oncology and Cancer Nursing in Paris, 29 October - 2 November 1995 |
| topic | Cytostatikum (DE-588)4068347-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Cytostatikum Pharmakotherapie Krebs Medizin Konferenzschrift 1995 Paris |
| volume_link | (DE-604)BV001893745 |
| work_keys_str_mv | AT postmuspietere themanagementofcancerpatientsseparateresearchexperienceswithgemcitabinehclanddab389il2fusionproteinbasedonscientificproceedingsofanelilillyandcompanysatellitesymposiumatthe8theuropeanconferenceonclinicaloncologyandcancernursinginparis29october2november199 AT europeanconferenceonclinicaloncologyandcancernursingparis themanagementofcancerpatientsseparateresearchexperienceswithgemcitabinehclanddab389il2fusionproteinbasedonscientificproceedingsofanelilillyandcompanysatellitesymposiumatthe8theuropeanconferenceonclinicaloncologyandcancernursinginparis29october2november199 |